"Effect examination of infliximab to the effect insufficient example and the example of effect decrease of the 1st TNF inhibitor in rheumatoid arthritis "

"Effect examination of infliximab to the effect insufficient example and the example of effect decrease of the 1st TNF inhibitor in rheumatoid arthritis " - Effect examination of infliximab to an anti-TNF invalid example

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007786

Enrollment

Registered

2012-04-19

Start date

2012-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

infliximab plus methotrexate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient whom is prescribing TNF inhibitors other than infliximab for the patient, and the disease activity (DAS28(4)-ESR >3.2, SDAI>11, or CDAI>10) more than the degree of middle class is maintaining over 12 or more weeks

Exclusion criteria

Exclusion criteria: "1) The patient who is having infliximab medical treatment already experienced 2) The patient who cannot prescribe a methotrexate tablet for the patient 3) The patient who is experienced in TNF inhibitors as for more than 2 agent 4) In addition, the patient who judged that a research doctor was unsuitable "

Design outcomes

Primary

Measure	Time frame
the remission rate of 1-2years after(DAS28(4)-CRP<2.3 or DAS28(4)-ESR<2.6 or SDAI<3.3 or CDAI<2.8)	—

Secondary

Measure	Time frame
the low disease activity maintenance rate of 1-2 years after (DAS28(4)-ESR<3.2 or SDAI<11 or CDAI<10 the low disease activity maintenance rate of 1-2 years after (DAS28(4)-ESR<3.2 or SDAI<11 or CDAI<10	—

Countries

Japan

Contacts

Public ContactKoichi Amano

Saitama Medical Center. Saitama Medical University Department of Rheumatology & Clinical Immunology

amanokoi@saitama-med.ac.jp0492283859

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

&quot;Effect examination of infliximab to the effect insufficient example and the example of effect decrease of the 1st TNF inhibitor in rheumatoid arthritis &quot;